ReviewBiomarker research2026
Isolation and typing techniques for circulating tumor cells.
Review in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Consolidated Evidence and New Frontiers of Liquid Biopsy in Lung Cancer: A Narrative Review.Cells · 2026Review
- Review
- Non-Invasive Diagnosis of Early Breast Cancer: Current and Emerging Liquid Biopsy Biomarkers.Cancers · 2026Review
- The role of liquid biopsy in the molecular characterization of HPV-related cancers.Folia microbiologica · 2026Review
- Diagnostic and Prognostic Utility of Cell-Surface Vimentin Positive Circulating Tumor Cells in Breast Cancer Using an Automated Negative Selection Platform.Diseases (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Circulating tumor cells (CTCs) are tumor cells that detach from primary tumors or metastatic sites and enter the peripheral blood. As an important biomarker for liquid biopsy, their detection and analysis have offered a promising avenue in early diagnosis, treatment response monitoring, and prognosis evaluation of tumors. Given the extreme rarity and high heterogeneity of CTCs, efficient and accurate separation and typing have become a primary research focus. This article systematically reviews the mainstream technologies for CTC separation and enrichment, including positive/negative selection based on immune markers, size/deformation/charge separation based on physical properties, and emerging microfluidic platforms; Furthermore, we discuss subtyping strategies for CTC phenotypes and genotypes, encompassing the combined application of surface markers such as EpCAM, CK, Vimentin, gene mutation and copy number variation analysis, transcriptome and proteomic feature analysis, etc.; Additionally, we highlight advancements in functional evaluation techniques such as single-cell culture, metabolic labeling, and in vivo tracking which provide insights into the stemness, drug resistance, and metastatic propensity of CTCs. Finally, we explore the prospects of integrating artificial intelligence and multi omics in CTC typing, pointing out that despite rapid technological progress, challenges in standardization, detection sensitivity, and clinical validation remain significant hurdles to their routine translational application. The review aims to provide a technical framework and cutting-edge perspective for CTC research, and promote its application in personalized tumor management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.